Clinical trial
Efficacy and Safety of Everolimus in de Novo Heart Transplant Recipients
NCT00150046 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00150046 |
|---|---|
| Title | Efficacy and Safety of Everolimus in de Novo Heart Transplant Recipients |
| Official title | A 12-month, Multicenter, Randomized, Open-label Non-inferiority Study of Renal Function and Efficacy Comparing Concentration-controlled Certican (1.5 mg/Day Starting Dose) With Reduced Neoral Dose Versus MMF With Standard Neoral Dose in de Novo Heart Transplant Recipients |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Heart Transplantation |
| Intervention type | Drug |
| Interventions | Everolimus |
| Enrollment | 176 |
| Start date | Dec 1, 2004 |
| Primary completion | May 1, 2007 |
| First posted | Sep 8, 2005 |
| Last update posted | Feb 11, 2020 |
| Countries | Germany, Switzerland |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: